SMMT Earnings Summit Therapeutics Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–29 of 29
| Q2 2026 | 2026-06-30 | -0.52 | 2026-07-23 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.24 | 2026-04-30 | 10-Q |
| FY 2025 | 2025-12-31 | -1.44 | 2026-02-23 | 10-K |
| Q3 2025 | 2025-09-30 | -1.16 | 2025-10-20 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.85 | 2026-07-23 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.09 | 2026-04-30 | 10-Q |
| FY 2025 | 2024-12-31 | -0.31 | 2026-02-23 | 10-K |
| Q3 2025 | 2024-09-30 | -0.22 | 2025-10-20 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.15 | 2025-08-11 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.06 | 2025-05-01 | 10-Q |
| FY 2025 | 2023-12-31 | -0.99 | 2026-02-23 | 10-K |
| Q3 2024 | 2023-09-30 | -0.98 | 2024-10-30 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.03 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.43 | 2024-05-01 | 10-Q |
| FY 2024 | 2022-12-31 | -0.41 | 2025-02-24 | 10-K |
| Q3 2023 | 2022-09-30 | -0.37 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.27 | 2023-08-09 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.15 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -0.67 | 2023-03-09 | 10-K |
| Q3 2022 | 2021-09-30 | -0.67 | 2022-11-09 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.48 | 2022-08-11 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.21 | 2022-05-11 | 10-Q |
| FY 2021 | 2020-12-31 | -0.76 | 2022-03-17 | 10-K |
| Q3 2021 | 2020-09-30 | -0.58 | 2021-11-15 | 10-Q |
| Q2 2021 | 2020-06-30 | -0.32 | 2021-08-12 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.09 | 2021-05-17 | 10-Q |
| FY 2020 | 2019-12-31 | -0.89 | 2021-03-31 | 10-K |
| Q3 2020 | 2019-09-30 | -0.63 | 2020-11-16 | 10-Q |
| FY 2020 | 2019-01-31 | 0.63 | 2021-03-31 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.